EGFR and non-small cell lung carcinoma: By targeting the orthosteric ATP-binding site in the interlobar cleft, TKIs compete with ATP and thereby blunt aberrant EGFR activation caused by oncogenic mutations such as L858R, which has revolutionized the treatment of NSCLC.